Evotec

Reminder! 𝗧𝗵𝗲 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗽𝗲𝗿𝗶𝗼𝗱 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗘𝘃𝗼𝘁𝗲𝗰-𝗦𝗖𝗧 𝗽𝗿𝗶𝘇𝗲 𝗳𝗼𝗿 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 𝗶𝗻 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗗𝗲𝘀𝗶𝗴𝗻 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗰𝗹𝗼𝘀𝗶𝗻𝗴 𝘀𝗼𝗼𝗻! The assessment panel is keen to recognize people who have demonstrated excellence in drug design resulting in highly informative novel molecules significantly impacting the drug discovery project. Good luck! 𝗙𝗶𝗻𝗱 𝗼𝘂𝘁 𝗺𝗼𝗿𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗵𝗲𝗿𝗲 - https://hubs.ly/Q039nrsM0 Société de Chimie Thérapeutique SCT

Join us at ‘The Connected Lab’ ELRIG-Forum 2025 on 13 March 2025 in Darmstadt for our presentation, "2 million transcriptomes and beyond: Evotec's high-throughput transcriptomics platform ScreenSeq™ for drug development." Learn more about the event here- https://hubs.ly/Q0398nXL0 Discover how ScreenSeq is revolutionizing drug discovery by enabling large-scale transcriptome profiling with unparalleled efficiency. #ELRIG2025 #DrugDevelopment #Transcriptomics

In our latest blog post, we delve into 𝗥𝗡𝗔 𝘀𝗽𝗹𝗶𝗰𝗶𝗻𝗴 𝗺𝗼𝗱𝘂𝗹𝗮𝘁𝗼𝗿𝘀—𝗮 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝘁𝗼 𝘁𝗮𝗿𝗴𝗲𝘁 𝗽𝗿𝗲𝘃𝗶𝗼𝘂𝘀𝗹𝘆 '𝘂𝗻𝗱𝗿𝘂𝗴𝗴𝗮𝗯𝗹𝗲' 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀. By focusing on RNA splicing, we're pioneering new avenues in drug discovery, offering hope for conditions lacking effective treatments. Discover how Evotec's high-throughput RT-qPCR platform is revolutionizing the identification and profiling of RNA splicing modulators. Stay ahead in the evolving landscape of RNA-targeted drug discovery by exploring the 𝗳𝘂𝗹𝗹 𝗯𝗹𝗼𝗴 𝗽𝗼𝘀𝘁 𝗵𝗲𝗿𝗲- https://hubs.ly/Q038XPGN0 #DrugDiscovery #RNAsplicing #HitIdentification

Unlocking Quality by Design: A Comprehensive Introduction to QbD Principles in Drug Product Development Are you interested in understanding the fundamental concepts of Quality by Design (QbD) in drug product development? Join Episode 1 of our webinar series where Evotec's experts, Mirka Scarati and Zadeo Cimarosti, will guide you through the principles that align with ICH guidelines. How can a robust scientific understanding enhance your product development lifecycle? https://hubs.ly/Q038KGH60 If you are interested in the full "Mastering Quality by Design" series you can download all episodes on demand!

𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗲 𝗘𝘃𝗼𝘁𝗲𝗰’𝘀 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗮𝗻𝗱 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝘁𝗼 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗷𝗼𝘂𝗿𝗻𝗲𝘆 𝗘𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲: Multidisciplinary team with >85% success in validating tractable hits 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: Cutting edge compound management and advanced screening capabilities 𝗖𝗼𝗺𝗽𝗼𝘂𝗻𝗱 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻: Curated library of >850,000 compounds 𝗔𝗜/𝗠𝗟 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻: Innovative solutions to drive efficiency and success in Hit ID 𝗩𝗶𝘀𝗶𝘁 𝗼𝘂𝗿 𝘄𝗲𝗯𝘀𝗶𝘁𝗲 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲- https://hubs.ly/Q038XKYl0 #HitIdentification #DrugDiscovery

Evotec SE announces another major accomplishment in its long-standing neuroscience collaboration with Bristol Myers Squibb. The latest scientific achievement in the partnership has triggered a research payment of US$20 m to Evotec, enabling further development of a promising pre-clinical program in neurodegeneration. Read the full press release to learn more- https://hubs.ly/Q0395hpS0 #TogetherForMedicinesThatMatter #Neuroscience

A deep understanding of Absorption, Distribution, Metabolism, and Excretion (ADME) is essential for successful drug discovery and development. Now updated with the latest ICH M12 guidelines, the 6th edition of Cyprotex’s ADME Guide is your go-to resource for exploring physicochemical properties, drug metabolism, permeability, transporters, plasma protein binding, drug-drug interactions, and to understand how ADME data are interpreted and used. Join thousands of scientists who rely on this must-have resource for optimizing compound design and development. Download your free copy today! https://hubs.ly/Q038XQNV0 #cyprotex #theadmetoxspecialists

Evotec and Cyprotex are delighted to return to the SOT Annual Meeting and ToxExpo for its 64th edition! For us, it's more than just an event—it's a valued tradition that allows us to reunite with the vibrant toxicology community. We're bringing our expertise and innovative solutions to the forefront with three engaging exhibitor-hosted sessions: "Empowering Toxicology Studies with Automated Real-Time Data Analysis," "Leveraging AI and an Integrated NAMs Toolbox to Assess Multi-Organ Safety in Early Drug Discovery," and "Outsourcing in Drug Development: Focus on Efficiency." Don't miss out! Visit our event page to get all the details about our sessions, including speakers, dates, venue, and times. Explore our new resources section to learn more about our capabilities and request a meeting with our experts: https://hubs.ly/Q038LNSR0 We look forward to connecting with you! #SOT2025 #Toxicology #Innovation

Don't forget, the 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗽𝗲𝗿𝗶𝗼𝗱 𝗶𝘀 𝗻𝗼𝘄 𝗼𝗽𝗲𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲 𝟮𝟬𝟮𝟱 𝗘𝘃𝗼𝘁𝗲𝗰-𝗦𝗖𝗧 𝗣𝗿𝗶𝘇𝗲 𝗳𝗼𝗿 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 𝗶𝗻 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗗𝗲𝘀𝗶𝗴𝗻! The successful candidate will be selected based on outstanding innovation and applied state-of-the-art molecular design skills that have contributed to a demonstrated advance to drug discovery boundaries. Submissions preferably should be the subject of a published (or accepted) scientific article, cover a “break-through” discovery or innovative technology/method, and may include the application of machine learning (ML) and artificial intelligence (AI). 𝗧𝗵𝗲 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗱𝗲𝗮𝗱𝗹𝗶𝗻𝗲 𝗶𝘀 𝟭𝟱 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟱, and the winner will be invited to give a lecture at the 59th RICT in Orléans on 2 - 4 July 2025. 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗺𝗼𝗿𝗲 𝗮𝗻𝗱 𝗮𝗽𝗽𝗹𝘆 𝗵𝗲𝗿𝗲- https://hubs.ly/Q037-ztg0 Société de Chimie Thérapeutique SCT

Evotec SE today announced that its Chief Financial Officer, Laetitia Rouxel, will step down from her role of Chief Financial Officer effective 28 February 2025 and leave the Company effective 31 March 2025 to pursue other opportunities. Laetitia Rouxel joined Evotec in April 2023 as Chief Financial Officer and member of the Management Board of Evotec. Paul Hitchin has been appointed by the Supervisory Board to succeed Laetitia Rouxel, effective 1 March 2025. Read the full press release to learn more - https://hubs.ly/Q038dY6y0